Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, has received the Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its brensocatib intended for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), it was reported on Friday.
Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 being produced by Insmed for the treatment of NCFBE a severe, chronic pulmonary disorder in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage, and other inflammatory diseases.
The PRIME designation is aimed at supporting development of medicines that target unmet medical requirements. To be eligible, treatment candidates must showcase the potential to provide a major therapeutic advantage over present treatments, or benefit patients without treatment options, based on early clinical data. The product has received PRIME designation based on positive results from the global, randomised, double-blind, placebo-controlled Phase 2 WILLOW study of brensocatib in adults with NCFBE.
Reportedly, Insmed plans to start the registrational phase three ASPEN trial of the product in patients with NCFBE by the end of 2020.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review